Immuneering Corporation
US ˙ NasdaqGM ˙ US45254E1073

Introduktion

Denne side giver en omfattende analyse af den kendte insiderhandelshistorie for Laurie Keating. Insidere er embedsmænd, direktører eller betydelige investorer i en virksomhed. Det er ulovligt for insidere at foretage handler i deres virksomheder baseret på specifik, ikke-offentlig information. Dette betyder ikke, at det er ulovligt for dem at handle i deres egne virksomheder. De skal dog rapportere alle handler til SEC via en formular 4. På trods af disse begrænsninger tyder akademisk forskning på, at insidere - generelt - har en tendens til at klare sig bedre end markedet i deres egne virksomheder.

Gennemsnitlig handelsrentabilitet

Den gennemsnitlige handelsrentabilitet er det gennemsnitlige afkast af alle køb på det åbne marked foretaget af insideren i de sidste tre år. For at beregne dette undersøger vi ethvert åbent marked, uplanlagte køb foretaget af insideren, eksklusive alle handler, der var markeret som en del af en 10b5-1-handelsplan. Vi beregner derefter den gennemsnitlige præstation for disse handler over 3, 6 og 12 måneder, idet vi tager et gennemsnit af hver af disse varigheder for at generere en endelig præstationsmåling for hver handel. Endelig tager vi et gennemsnit af alle præstationsmålingerne for at beregne en præstationsmåling for insideren. Denne liste inkluderer kun insidere, der har foretaget mindst tre handler i de sidste to år.

Hvis denne insiderhandelsrentabilitet er "N/A", så har insideren enten ikke foretaget nogen køb på det åbne marked i de sidste tre år, eller de handler, de har foretaget, er for nye til at beregne en pålidelig præstationsmåling.

Opdateringsfrekvens: Dagligt

Se listen over de mest profitable insiderhandlere.

Virksomheder med rapporterede insider-stillinger

SEC-registreringen viser, at Laurie Keating har rapporteret besiddelser eller handler i følgende virksomheder:

Sikkerhed Titel Senest indberettede beholdninger
US:PEPG / PepGen Inc. Director 4.166
US:IMRX / Immuneering Corporation Director 14.000
US:IMGO / Imago BioSciences Inc Director 23.809
US:ALNY / Alnylam Pharmaceuticals, Inc. EVP, Chief Legal Officer 1.124
Sådan fortolkes diagrammerne

Følgende diagrammer viser aktieudviklingen for værdipapirer efter hver åben-marked, ikke-planlagt handel foretaget af Laurie Keating. Ikke-planlagt handel er handler, der ikke blev foretaget som en del af en 10b5-1-handelsplan. Aktieudviklingen er kortlagt som den kumulative procentvise ændring i aktiekursen. For eksempel, hvis en insiderhandel blev foretaget den 1. januar 2019, vil diagrammet vise den daglige procentvise ændring af værdipapiret til i dag. Hvis aktiekursen skulle gå fra $10 til $15 i løbet af denne tid, ville den kumulative procentvise ændring i aktiekursen være 50%. En prisændring fra 10 USD til 20 USD ville være 100 %, og en ændring i prisen på 10 USD til 5 USD ville være -50 %.

I sidste ende forsøger vi at bestemme, hvor tæt insiderens handler korrelerer med merafkast (positive eller negative) i aktiekursen for at se, om insideren timing deres handler til at drage fordel af insiderinformation. Overvej situationen, hvor en insider gjorde dette. I denne situation ville vi forvente enten (a) positive afkast efter køb eller (b) negative afkast efter salg. I tilfælde af (a) vil KØB-diagrammet vise en række opadskrånende kurver, der indikerer positive afkast efter hver købstransaktion. I tilfælde af (b) vil SALE-diagrammet vise en række nedadgående kurver, der indikerer negative afkast efter hver salgstransaktion.

Dette alene er dog ikke nok til at drage konklusioner. Hvis for eksempel aktiekursen i selskabet var i en ikke-cyklisk stigning over mange år, så ville vi forvente, at alle efterkøbsgrundene var opadgående. Ligeledes ville ikke-cykliske fald over mange år resultere i nedadgående post-trade plots. Ingen af disse diagrammer tyder på insiderhandel.

Den stærkeste indikator ville være en situation, hvor aktiekursen var ekstremt cyklisk, og der var både positive signaler i KØB-diagrammet og negative plots på SALG-diagrammet. Denne situation ville i høj grad tyde på en insider, der havde timing af handler til deres økonomiske fordel.

Insiderkøb IMRX / Immuneering Corporation – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i IMRX / Immuneering Corporation. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
2022-05-16 IMRX KEATING LAURIE 7.000 5,0000 7.000 5,0000 35.000 141 15.0000 70.000 200,00
2021-08-03 IMRX KEATING LAURIE 7.000 15,0000 7.000 15,0000 105.000

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

IMRX / Immuneering Corporation Insider Trades
Insidersalg IMRX / Immuneering Corporation – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i IMRX / Immuneering Corporation. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

IMRX / Immuneering Corporation Insider Trades
Insiderkøb PEPG / PepGen Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i IMRX / Immuneering Corporation. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
2022-05-06 PEPG KEATING LAURIE 4.166 12,0000 4.166 12,0000 49.992 283 17.7000 23.746 47,50

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

PEPG / PepGen Inc. Insider Trades
Insidersalg PEPG / PepGen Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i IMRX / Immuneering Corporation. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

PEPG / PepGen Inc. Insider Trades
Insiderhandelshistorie

Denne tabel viser den komplette liste over insiderhandler foretaget af Laurie Keating som oplyst til Securities Exchange Commission (SEC).

Fil dato Transdato Form Ticker Sikkerhed Kode 10b5-1 Aktier Resterende aktier Procent
Lave om
Del
Pris
Tran
Værdi
Tilbage
Værdi
2023-01-19 2022-05-06 4 PEPG PepGen Inc.
Common Stock
P - Purchase 4.166 4.166 12,00 49.992 49.992
2022-05-17 2022-05-16 4 IMRX Immuneering Corp
Class A Common Stock
P - Purchase 7.000 14.000 100,00 5,00 35.000 70.000
2022-05-10 2022-05-06 4 PEPG PepGen Inc.
Stock Option (Right to Buy)
A - Award 5.833 5.833
2021-11-19 2021-11-17 4 IMGO Imago BioSciences, Inc.
Stock Option (Right to Buy)
A - Award 23.809 23.809
2021-08-09 2021-08-05 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy)
M - Exercise X -7.876 1.124 -87,51
2021-08-09 2021-08-05 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2015 (right to buy)
M - Exercise X -2.124 11.876 -15,17
2021-08-09 2021-08-05 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -10.000 5.132 -66,09 188,95 -1.889.500 969.691
2021-08-09 2021-08-05 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
M - Exercise X 2.124 15.132 16,33 88,95 188.930 1.345.991
2021-08-09 2021-08-05 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
M - Exercise X 7.876 13.008 153,47 88,95 700.570 1.157.062
2021-08-04 2021-08-03 4 IMRX Immuneering Corp
Class A Common Stock
P - Purchase 7.000 7.000 15,00 105.000 105.000
2021-07-14 2021-07-12 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy)
M - Exercise X -5.000 9.000 -35,71
2021-07-14 2021-07-12 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy)
M - Exercise X -1.812 17.188 -9,54
2021-07-14 2021-07-12 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -5.000 5.132 -49,35 178,95 -894.750 918.371
2021-07-14 2021-07-12 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -1.812 10.132 -15,17 179,00 -324.348 1.813.628
2021-07-14 2021-07-12 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
M - Exercise X 5.000 11.944 72,00 88,95 444.750 1.062.419
2021-07-14 2021-07-12 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
M - Exercise X 1.812 6.944 35,31 85,00 154.020 590.240
2021-06-11 2021-06-09 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -1.734 5.132 -25,25 154,00 -267.036 790.328
2021-04-21 2021-04-20 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
F - Taxes -75 6.866 -1,08 134,42 -10.081 922.916
2021-04-21 2021-04-20 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
F - Taxes -2.014 6.941 -22,49 131,75 -265.344 914.477
2021-04-21 2021-04-19 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
A - Award 4.518 8.955 101,83
2021-02-26 2021-02-24 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy)
A - Award 17.846 17.846
2021-02-16 2021-02-12 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
F - Taxes -106 4.437 -2,33 153,54 -16.275 681.257
2021-02-16 2021-02-12 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
F - Taxes -1.857 4.543 -29,02 156,00 -289.692 708.708
2021-02-16 2021-02-11 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2017 (right to buy)
A - Award 4.584 10.000 84,64
2021-02-16 2021-02-11 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
A - Award 4.166 6.400 186,48
2021-01-15 2021-01-13 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy)
M - Exercise X -6.000 19.000 -24,00
2021-01-15 2021-01-13 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy)
M - Exercise X -3.027 2.164 -58,31
2021-01-15 2021-01-13 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -1.027 2.234 -31,49 174,00 -178.698 388.716
2021-01-15 2021-01-13 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -3.000 3.261 -47,92 170,00 -510.000 554.370
2021-01-15 2021-01-13 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -5.000 6.261 -44,40 169,00 -845.000 1.058.109
2021-01-15 2021-01-13 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
M - Exercise X 6.000 11.261 114,05 85,00 510.000 957.185
2021-01-15 2021-01-13 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
M - Exercise X 3.027 5.261 135,50 77,40 234.290 407.201
2021-01-13 2021-01-12 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy)
M - Exercise X -13.000 5.191 -71,46
2021-01-13 2021-01-12 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy)
M - Exercise X -1.941 2.370 -45,02
2021-01-13 2021-01-12 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -3.000 2.234 -57,32 165,00 -495.000 368.610
2021-01-13 2021-01-12 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -11.941 5.234 -69,53 159,00 -1.898.619 832.206
2021-01-13 2021-01-12 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
M - Exercise X 13.000 17.175 311,38 77,40 1.006.200 1.329.345
2021-01-13 2021-01-12 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
M - Exercise X 1.941 4.175 86,88 42,22 81.949 176.268
2021-01-13 2021-01-11 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -758 2.234 -25,33 154,00 -116.732 344.036
2020-07-14 2020-07-13 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy)
M - Exercise X -6.250 7.500 -45,45
2020-07-14 2020-07-13 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy)
M - Exercise X -23.809 18.191 -56,69
2020-07-14 2020-07-13 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy)
M - Exercise X -1.941 4.311 -31,05
2020-07-14 2020-07-13 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2017 (right to buy)
M - Exercise X -3.750 5.416 -40,91
2020-07-14 2020-07-13 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -9.530 2.992 -76,11 162,24 -1.546.147 485.422
2020-07-14 2020-07-13 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -15.618 12.522 -55,50 161,32 -2.519.496 2.020.049
2020-07-14 2020-07-13 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -14.236 28.140 -33,59 160,52 -2.285.163 4.517.033
2020-07-14 2020-07-13 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -1.061 42.376 -2,44 159,22 -168.932 6.747.107
2020-07-14 2020-07-13 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -2.323 43.437 -5,08 158,27 -367.661 6.874.774
2020-07-14 2020-07-13 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -4.482 45.760 -8,92 157,16 -704.391 7.191.642
2020-07-14 2020-07-13 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
M - Exercise X 6.250 50.242 14,21 119,13 744.562 5.985.329
2020-07-14 2020-07-13 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
M - Exercise X 3.750 43.992 9,32 119,13 446.738 5.240.767
2020-07-14 2020-07-13 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
M - Exercise X 23.809 40.242 144,89 77,40 1.842.817 3.114.731
2020-07-14 2020-07-13 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
M - Exercise X 1.941 16.433 13,39 42,22 81.949 693.801
2020-04-22 2020-04-20 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy)
M - Exercise X -10.000 42.000 -19,23
2020-04-22 2020-04-20 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -10.000 14.492 -40,83 139,00 -1.390.000 2.014.388
2020-04-22 2020-04-20 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
M - Exercise X 10.000 24.492 69,00 77,40 774.000 1.895.681
2020-04-09 2020-04-07 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
F - Taxes -75 14.492 -0,51 105,63 -7.922 1.530.790
2020-04-09 2020-04-07 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
F - Taxes -1.858 14.567 -11,31 104,75 -194.626 1.525.893
2020-04-09 2020-04-07 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
A - Award 4.167 16.425 33,99
2020-02-28 2020-02-26 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy)
A - Award 24.554 24.554
2020-02-12 2020-02-10 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy)
M - Exercise X -10.000 52.000 -16,13
2020-02-12 2020-02-10 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -10.000 12.258 -44,93 129,00 -1.290.000 1.581.282
2020-02-12 2020-02-10 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
M - Exercise X 10.000 22.258 81,58 77,40 774.000 1.722.769
2020-02-12 2020-01-27 4/A ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
M - Exercise X 3.663 12.258 42,62 77,40 283.516 948.769
2020-01-31 2020-01-29 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy)
M - Exercise X -6.337 62.000 -9,27
2020-01-31 2020-01-29 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale -6.337 8.595 -42,44 119,00 -754.103 1.022.805
2020-01-31 2020-01-29 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
M - Exercise X 6.337 14.932 73,73 77,40 490.484 1.155.737
2020-01-29 2020-01-27 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy)
M - Exercise X -3.663 68.337 -5,09
2020-01-29 2020-01-27 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy)
M - Exercise X -9.374 6.252 -59,99
2020-01-29 2020-01-27 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2016 (right to buy)
M - Exercise X -25.000 0 -100,00
2020-01-29 2020-01-27 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -190 8.595 -2,16 120,21 -22.840 1.033.205
2020-01-29 2020-01-27 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -6.667 8.785 -43,15 119,53 -796.907 1.050.071
2020-01-29 2020-01-27 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -13.084 15.452 -45,85 118,61 -1.551.893 1.832.762
2020-01-29 2020-01-27 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -4.100 28.536 -12,56 117,67 -482.447 3.357.831
2020-01-29 2020-01-27 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -13.631 32.636 -29,46 116,43 -1.587.057 3.799.809
2020-01-29 2020-01-27 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -3.365 46.267 -6,78 115,55 -388.826 5.346.152
2020-01-29 2020-01-27 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
M - Exercise X 25.000 49.632 101,49 42,22 1.055.500 2.095.463
2020-01-29 2020-01-27 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
M - Exercise X 9.374 24.632 61,44 42,22 395.770 1.039.963
2019-12-26 2019-12-23 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2017 (right to buy)
A - Award 4.583 9.166 100,00
2019-11-26 2019-11-22 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2017 (right to buy)
A - Award 4.583 4.583
2019-11-26 2019-10-10 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
J - Other 10 434 2,36
2019-08-07 2019-08-06 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2016 (right to buy)
A - Award 6.250 25.000 33,33
2019-08-07 2019-08-06 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2015 (right to buy)
A - Award 3.500 14.000 33,33
2019-08-07 2019-07-11 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
J - Other 49 424 13,07
2019-06-07 2019-06-05 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2016 (right to buy)
A - Award 6.250 18.750 50,00
2019-06-07 2019-04-09 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
J - Other 41 375 12,28
2019-06-07 2018-10-18 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
J - Other 14 334 4,38
2019-03-01 2019-02-28 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy)
A - Award 25.000 25.000
2018-09-28 2018-09-27 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2016 (right to buy)
A - Award 6.250 12.500 100,00
2018-09-28 2018-09-27 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2015 (right to buy)
A - Award 3.500 10.500 50,00
2018-08-23 2018-08-21 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2015 (right to buy)
A - Award 3.500 7.000 100,00
2018-08-14 2018-08-13 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
F - Taxes -605 15.258 -3,81 90,95 -55.025 1.387.715
2018-08-14 2018-08-13 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
A - Award 1.363 15.863 9,40
2018-08-14 2018-08-10 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2014 (right to buy)
A - Award 1.984 5.958 49,92
2018-08-14 2018-07-10 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
J - Other 32 320 11,11
2018-06-22 2018-06-20 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy)
M - Exercise X -1.563 15.626 -9,09
2018-06-22 2018-06-20 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -1.563 14.500 -9,73 105,04 -164.178 1.523.080
2018-06-22 2018-06-20 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
M - Exercise X 1.563 16.063 10,78 42,22 65.990 678.180
2018-06-22 2018-04-16 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
J - Other 31 288 12,06
2018-03-22 2018-03-20 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy)
M - Exercise X -1.562 17.189 -8,33
2018-03-22 2018-03-20 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -300 14.500 -2,03 152,79 -45.837 2.215.455
2018-03-22 2018-03-20 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -200 14.800 -1,33 151,48 -30.296 2.241.904
2018-03-22 2018-03-20 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -500 15.000 -3,23 149,97 -74.985 2.249.550
2018-03-22 2018-03-20 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -462 15.500 -2,89 147,79 -68.279 2.290.745
2018-03-22 2018-03-20 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -100 15.962 -0,62 146,36 -14.636 2.336.198
2018-03-22 2018-03-20 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
M - Exercise X 1.562 16.062 10,77 42,22 65.948 678.138
2018-03-14 2018-03-13 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy)
M - Exercise X -10.000 72.000 -12,20
2018-03-14 2018-03-13 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -10.000 14.500 -40,82 150,00 -1.500.000 2.175.000
2018-03-14 2018-03-13 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
M - Exercise X 10.000 24.500 68,97 77,40 774.000 1.896.300
2018-03-14 2018-03-12 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy)
M - Exercise X -10.000 82.000 -10,87
2018-03-14 2018-03-12 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -10.000 14.500 -40,82 140,00 -1.400.000 2.030.000
2018-03-14 2018-03-12 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
M - Exercise X 10.000 24.500 68,97 77,40 774.000 1.896.300
2018-03-05 2018-03-01 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy)
A - Award 13.750 13.750
2018-01-03 2017-12-29 4 ALKS ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy)
M - Exercise -3.000 92.000 -3,16
2018-01-03 2017-12-29 4 ALKS ALNYLAM PHARMACEUTICALS, INC.
Common Stock
M - Exercise 3.000 14.500 26,09 77,40 232.200 1.122.300
2017-12-21 2017-12-20 4 ALKS ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy)
M - Exercise X -6.249 18.751 -25,00
2017-12-21 2017-12-20 4 ALKS ALNYLAM PHARMACEUTICALS, INC.
Performance Based Stock Option 2016 (right to buy)
A - Award 6.250 6.250
2017-12-21 2017-12-20 4 ALKS ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -300 11.500 -2,54 122,53 -36.760 1.409.133
2017-12-21 2017-12-20 4 ALKS ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -1.900 11.800 -13,87 121,67 -231.182 1.435.761
2017-12-21 2017-12-20 4 ALKS ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -4.049 13.700 -22,81 120,88 -489.456 1.656.101
2017-12-21 2017-12-20 4 ALKS ALNYLAM PHARMACEUTICALS, INC.
Common Stock
M - Exercise X 6.249 17.749 54,34 42,22 263.833 749.363
2017-12-05 2017-12-01 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy)
M - Exercise X -30.000 95.000 -24,00
2017-12-05 2017-12-01 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -6.199 11.500 -35,02 137,29 -851.061 1.578.835
2017-12-05 2017-12-01 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -9.700 17.699 -35,40 136,50 -1.324.050 2.415.914
2017-12-05 2017-12-01 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -7.500 27.399 -21,49 135,56 -1.016.700 3.714.208
2017-12-05 2017-12-01 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -3.801 34.899 -9,82 134,59 -511.577 4.697.056
2017-12-05 2017-12-01 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -2.800 38.700 -6,75 133,37 -373.436 5.161.419
2017-12-05 2017-12-01 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
M - Exercise X 30.000 41.500 260,87 77,40 2.322.000 3.212.100
2017-11-08 2017-11-06 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2015 (right to buy)
A - Award 3.500 3.500
2017-07-11 2017-07-07 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2014 (right to buy)
A - Award 1.987 3.974 100,00
2017-05-31 2017-05-30 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Common Stock
P - Purchase 11.500 11.500 65,35 751.502 751.502
2016-12-22 2016-12-20 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy)
A - Award 25.000 25.000
2016-02-03 2016-02-01 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2014 (right to buy)
A - Award 1.987 1.987
2015-12-22 2015-12-18 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy)
A - Award 14.000 14.000
2015-05-05 2015-05-01 4 ALNY ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy)
A - Award 5.959 5.959
P
Åbent marked eller privat køb af ikke-afledte eller afledte værdipapirer
S
Åbent marked eller privat salg af ikke-afledte eller afledte værdipapirer
A
Tildeling, tildeling eller anden erhvervelse af værdipapirer fra virksomheden (såsom en option)
C
Konvertering af derivat
D
Salg eller overførsel af værdipapirer tilbage til virksomheden
F
Betaling af udnyttelseskurs eller skatteforpligtelse ved brug af en del af værdipapirer modtaget fra selskabet
G
Gave af værdipapirer af eller til insideren
K
Aktieswaps og lignende sikringstransaktioner
M
Udnyttelse eller konvertering af afledt værdipapir modtaget fra virksomheden (såsom en option)
V
En transaktion rapporteret frivilligt på formular 4
J
Andet (ledsaget af en fodnote, der beskriver transaktionen)